Literature DB >> 22705382

Standardized analysis of frequency and severity of complications after robot-assisted radical cystectomy.

Bertram E Yuh1, Michael Nazmy, Nora H Ruel, Jason T Jankowski, Anita R Menchaca, Robert R Torrey, Jennifer A Linehan, Clayton S Lau, Kevin G Chan, Timothy G Wilson.   

Abstract

BACKGROUND: Comprehensive and standardized reporting of adverse events after robot-assisted radical cystectomy (RARC) and urinary diversion for bladder cancer is necessary to evaluate the magnitude of morbidity for this complex operation.
OBJECTIVE: To accurately identify and assess postoperative morbidity after RARC using a standardized reporting system. DESIGN, SETTING, AND PARTICIPANTS: A total of 241 consecutive patients underwent RARC, extended pelvic lymph node dissection, and urinary diversion between 2003 and 2011. In all, 196 patients consented to a prospective database, and they are the subject of this report. Continent diversions were performed in 68% of cases. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All complications within 90 d of surgery were defined and categorized by a five-grade and 10-domain modification of the Clavien system. Univariable and multivariable logistic regression analyses were used to identify predictors of complications. Grade 1-2 complications were categorized as minor, and grade 3-5 complications were categorized as major. All blood transfusions were recorded as grade ≥2. RESULTS AND LIMITATIONS: Eighty percent of patients (156 of 196 patients) experienced a complication of any grade ≤90 d after surgery. A total of 475 adverse events (113 major) were recorded, with 365 adverse events (77%) occurring ≤30 d after surgery. Sixty-eight patients (35%) experienced a major complication within the first 90 d. Other than blood transfusions given (86 patients [43.9%]), infectious, gastrointestinal, and procedural complications were the most common, at 16.2%, 14.1%, and 10.3%, respectively. Age, comorbidity, preoperative hematocrit, estimated blood loss, and length of surgery were predictive of a complication of any grade, while comorbidity, preoperative hematocrit, and orthotopic diversion were predictive of major complications. The 90-d mortality rate was 4.1%. The main limitation is lack of a control group.
CONCLUSIONS: Analysis of postoperative morbidity following RARC demonstrates a considerable complication rate, though the rate is comparable to contemporary open series that followed similar reporting guidelines. This finding reinforces the need for complete and standardized reporting when evaluating surgical techniques and comparing published series.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22705382     DOI: 10.1016/j.eururo.2012.06.007

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  35 in total

1.  The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer.

Authors:  Adam C Reese; Mark W Ball; Nilay Gandhi; Michael A Gorin; George J Netto; Trinity J Bivalacqua; Mark P Schoenberg
Journal:  Urology       Date:  2014-08       Impact factor: 2.649

Review 2.  Anesthetic considerations for robotic surgery.

Authors:  Jeong Rim Lee
Journal:  Korean J Anesthesiol       Date:  2014-01-28

3.  Intraoperative laparoscopic complications for urological cancer procedures.

Authors:  Sergio Fernández-Pello Montes; Ivan Gonzalez Rodríguez; Rodrigo Gil Ugarteburu; Luis Rodríguez Villamil; Begoña Diaz Mendez; Patricio Suarez Gil; Javier Mosquera Madera
Journal:  World J Clin Cases       Date:  2015-05-16       Impact factor: 1.337

4.  90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study.

Authors:  Hooman Djaladat; Behrod Katebian; Soroush T Bazargani; Gus Miranda; Jie Cai; Anne K Schuckman; Siamak Daneshmand
Journal:  World J Urol       Date:  2016-10-12       Impact factor: 4.226

Review 5.  Lymphadenectomy with robotic cystectomy.

Authors:  John W Davis; Ashish M Kamat
Journal:  Curr Urol Rep       Date:  2013-02       Impact factor: 3.092

Review 6.  Current Status of Robot-Assisted Radical Cystectomy and Intracorporeal Urinary Diversion.

Authors:  Raj Kurpad; Michael Woods; Raj Pruthi
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

Review 7.  The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update.

Authors:  Norm D Smith; Erik P Castle; Mark L Gonzalgo; Robert S Svatek; Alon Z Weizer; Jeffrey S Montgomery; Raj S Pruthi; Michael E Woods; Matthew K Tollefson; Badrinath R Konety; Ahmad Shabsigh; Tracey Krupski; Daniel A Barocas; Atreya Dash; Marcus L Quek; Adam S Kibel; Dipen J Parekh
Journal:  BJU Int       Date:  2015-02       Impact factor: 5.588

8.  Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.

Authors:  Bernard H Bochner; Guido Dalbagni; Daniel D Sjoberg; Jonathan Silberstein; Gal E Keren Paz; S Machele Donat; Jonathan A Coleman; Sheila Mathew; Andrew Vickers; Geoffrey C Schnorr; Michael A Feuerstein; Bruce Rapkin; Raul O Parra; Harry W Herr; Vincent P Laudone
Journal:  Eur Urol       Date:  2014-12-08       Impact factor: 20.096

9.  Readmission after robot-assisted radical cystectomy: outcomes and predictors at 90-day follow-up.

Authors:  Ali Al-Daghmin; Ahmed Aboumohamed; Rakeeba Din; Aabroo Khan; Syed Johar Raza; Jenna Sztorc; Diana Mehedint; Mohammad Sharif; Yi Shi; Gregory Wilding; Khurshid A Guru
Journal:  Urology       Date:  2014-02       Impact factor: 2.649

10.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.